CD55蛋白在肺癌中的表达及临床意义

Analysis of the expression and clinical significance of CD55 in lung cancer

检测肺癌血清中CD55(complement decay-accelerating factor,CD55)的表达水平及其临床意义。采集42例良性患者和48例肺癌患者的血清和临床病例检测指标,检测CD55在肺癌血清中的表达水平,分析CD55表达水平与患者临床参数之间的关系,检测CD55诊断良恶肿瘤和生存评估效果。CD55 mRNA表达水平在肺鳞癌组织中下降;CD55在患者血清中表达水平显著下降。TISIDB数据库分析发现,在LUAD中CD55表达水平与CD8+T细胞呈负相关;在LUSC中CD55表达水平与NK细胞、巨噬细胞和中性粒细胞呈显著正相关。受试者工作特征(receiver operating characteristic,ROC)曲线分析发现,CD55区分良恶肿瘤的效果比CEA、CA125、SCCA等临床肿瘤标志物,AUC值达到0.744.相关性统计分析表明,CD55表达与患者血清中甲胎蛋白、糖类抗原CA724和高尔基蛋白73呈显著相关,且CD55表达与肺癌患者凝血指标呈显著相关。此外,生存分析发现CD55低表达的肺癌患者生存时间更短,在早期肺癌中更明显。进一步用TISIDB分析发现CD55 mRNA表达LUAD和LUSC患者的生存和分期无显著相关性,与免疫亚型有显著相关性,与LUSC患者的分子亚型也有显著相关性。本研究表明CD55有潜力作为肺部良恶肿瘤诊断和预后生存评估的标志物。

To detect the expression level of CD55(complement decay-accelerating factor,CD55)in serum of patients’with lung cancer and explore the clinicopathological characteristics,this study collects the serum and clinical case detection indexes of 42 benign patients and 48 lung cancer patients,detects the expression level of CD55 in their serum,analyzes the relationship between the expression level of CD55 and the clinical parameters of patients,and investigates the performance of CD55 in diagnosing of benign from malignant nodules and survival assessment effect.It finds that CD55 mRNA expression levels decrease in lung squamous cell carcinoma tissues and CD55 expression levels in serum reduces significantly.TISIDB database analysis suggests that the expression level of CD55 in LUAD is negatively correlated with CD8+T cells,and the expression level of CD55 in LUSC is significantly positively correlated with NK cells,macrophages and neutrophils.Receiver operating characteristic(ROC)analysis shows that CD55 has a better effect on distinguishing benign tumors from other tumor markers such as CEA、CA125、SCCA,with an AUC value of 0.744.Correlation analysis proves that CD55 expression is significantly correlated with alpha-fetoprotein,carbohydrate antigen CA724 and Golgi protein 73 in serum of patients,and CD55 expression is significantly correlated with coagulation indexes in lung cancer patients.In addition,survival analysis indicates that lung cancer patients with low CD55 expression have shorter survival times,which is more pronounced in early-stage lung cancer.Further analysis by TISIDB finds that CD55 mRNA expression has no significant association with survival and tumor stage,however,which is significantly correlated with the immune subtypes of LUSC patients.There also exists a significant association with the molecular subtypes of LUSC patients.In conclusion,this study reveals that CD55 has the possibility to be used as a diagnostic and prognostic biomarker for lung cancer.